We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

153 hedge funds and large institutions have $1.4B invested in Acorda Therapeutics in 2013 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 68 increasing their positions, 45 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

51% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 45

38% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 16

25% more call options, than puts

Call options by funds: $4.22M | Put options by funds: $3.36M

6% more capital invested

Capital invested by funds: $1.32B → $1.4B (+$80.1M)

3% more funds holding

Funds holding: 148 → 153 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
153
Holders Change
+5
Holders Change %
+3.38%
% of All Funds
4.96%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
22
Increased
68
Reduced
45
Closed
16
Calls
$4.22M
Puts
$3.36M
Net Calls
+$855K
Net Calls Change
-$11.3M

Top Buyers

1
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans
Minnesota
+$17.9M
2
BFA
BlackRock Fund Advisors
California
+$11.6M
3
Goldman Sachs
Goldman Sachs
New York
+$9.3M
4
ClearBridge Investments
ClearBridge Investments
New York
+$7.92M
5
EAM
Eagle Asset Management
Florida
+$6.35M

Top Sellers

1
AG
Artal Group
Luxembourg
-$14.5M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$11.8M
3
Deutsche Bank
Deutsche Bank
Germany
-$10.9M
4
SCM
Sigma Capital Management
Connecticut
-$6.22M
5
SCA
SAC Capital Advisors
Connecticut
-$6.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$194M -$11.8M -2,748 -6%
BFA
2
BlackRock Fund Advisors
California
$90.2M +$11.6M +2,683 +14%
Vanguard Group
3
Vanguard Group
Pennsylvania
$86.7M +$2.7M +627 +3%
UBS AM
4
UBS AM
Illinois
$85M +$538K +125 +0.6%
EAM
5
Eagle Asset Management
Florida
$76.9M +$6.35M +1,475 +9%
OIM
6
Oracle Investment Management
Connecticut
$68M -$254K -59 -0.4%
Invesco
7
Invesco
Georgia
$51.1M +$1.2M +278 +2%
State Street
8
State Street
Massachusetts
$50.2M +$1.81M +421 +4%
Wellington Management Group
9
Wellington Management Group
Massachusetts
$46.8M +$4.2M +976 +9%
BIT
10
BlackRock Institutional Trust
California
$38.9M -$711K -165 -2%
AG
11
Artal Group
Luxembourg
$37.5M -$14.5M -3,374 -27%
BA
12
BlackRock Advisors
Delaware
$35.3M -$4.95M -1,149 -12%
Goldman Sachs
13
Goldman Sachs
New York
$33.5M +$9.3M +2,158 +36%
ClearBridge Investments
14
ClearBridge Investments
New York
$28.6M +$7.92M +1,839 +36%
TSW
15
Thompson Siegel & Walmsley
Virginia
$27.4M -$1.56M -363 -5%
FAM
16
Fred Alger Management
New York
$23.4M +$271K +63 +1%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$23.2M +$1.48M +343 +6%
SI
18
Scout Investments
Missouri
$22.3M +$1.1M +256 +5%
Northern Trust
19
Northern Trust
Illinois
$20.4M -$297K -69 -1%
HM
20
HealthCor Management
New York
$18.8M +$5.32M +1,235 +37%
JP Morgan Chase
21
JP Morgan Chase
New York
$18M -$1.87M -434 -9%
Thrivent Financial for Lutherans
22
Thrivent Financial for Lutherans
Minnesota
$17.6M +$17.9M +4,162 +3,384%
VOYA Investment Management
23
VOYA Investment Management
Georgia
$16M +$1.65M +384 +11%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$15.1M +$1.07M +248 +7%
TA
25
Teachers Advisors
New York
$12.4M +$94.8K +22 +0.7%
1
2 3 4 5

ACOR Hedge Fund Activity: Q3 2013 in Review

153 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2013, worth a combined $1.4B — up 6.1% from $1.32B a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new ACOR positions and 16 closed out — a net gain of 6 holders — while 68 added to existing stakes and 45 trimmed.

The largest buyer was Thrivent Financial for Lutherans, adding an estimated $17.9M. The largest seller was Artal Group, cutting an estimated $14.5M.

  • 153 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2013, up from 148 in Q2 2013.
  • Funds reported $1.4B of Acorda Therapeutics stock for Q3 2013, up 6.1% quarter-over-quarter.
  • 22 funds opened new Acorda Therapeutics positions in Q3 2013 and 16 closed out, a net change of +6 holders.
  • The largest Acorda Therapeutics buyer in Q3 2013 was Thrivent Financial for Lutherans, an estimated $17.9M added.
  • The largest Acorda Therapeutics seller in Q3 2013 was Artal Group, an estimated $14.5M sold.

Based on aggregated 13F filings for Q3 2013.